4//SEC Filing
Nabulsi Azmi 4
Accession 0001209191-21-030141
CIK 0001783183other
Filed
May 3, 8:00 PM ET
Accepted
May 4, 8:31 PM ET
Size
14.1 KB
Accession
0001209191-21-030141
Insider Transaction Report
Form 4
Nabulsi Azmi
Chief Operating Officer
Transactions
- Sale
Common Stock
2021-05-03$38.59/sh−5,753$221,994→ 770,157 total(indirect: By Trust) - Sale
Common Stock
2021-05-04$36.15/sh−1,968$71,150→ 768,189 total(indirect: By Trust) - Sale
Common Stock
2021-05-04$37.09/sh−1,400$51,921→ 766,789 total(indirect: By Trust) - Sale
Common Stock
2021-05-03$37.85/sh−4,290$162,360→ 775,910 total(indirect: By Trust) - Sale
Common Stock
2021-05-04$37.86/sh−1,089$41,231→ 765,700 total(indirect: By Trust)
Footnotes (6)
- [F1]All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.15 to $38.12. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.18 to $38.97. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.66 to $36.64. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.66 to $37.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.7550 to $38.06. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Phathom Pharmaceuticals, Inc.
CIK 0001783183
Entity typeother
Related Parties
1- filerCIK 0001791412
Filing Metadata
- Form type
- 4
- Filed
- May 3, 8:00 PM ET
- Accepted
- May 4, 8:31 PM ET
- Size
- 14.1 KB